Table 3_Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating

A systematic review and network meta-analysis of 34 Phase II/III randomized controlled trials evaluating pharmacological treatments for metabolic dysfunction-associated steatohepatitis (MASH). The analysis, authored by Mengshi Tang and published on figshare in June 2026, ranks therapies by efficacy for fibrosis improvement and MASH resolution, incorporating SGLT2 inhibitors and emerging combination therapies.

Use Cases

• Ranking drug efficacy for fibrosis improvement based on relative risk (RR) and confidence intervals reported in the meta-analysis.
• Comparing tolerability profiles of different drug classes based on discontinuation rates due to adverse events mentioned in the description.
• Identifying promising oral therapy options for MASH based on the analysis of SGLT2 inhibitor performance.
• Informing clinical trial design by highlighting evidence gaps, such as the need for larger Phase 3 trials for SGLT2 inhibitors.

Strengths

• Analysis is based on 34 studies from 33 unique publications, providing a substantial evidence base.
• Results include specific relative risk (RR) values and 95% confidence intervals for multiple drug classes, such as FGF21 analogs (RR 2.22) and SGLT2 inhibitors (RR 2.27).
• The study protocol is registered with PROSPERO (CRD420261292638), indicating a systematic methodology.

Limitations

• The dataset is a 29.3 KB DOCX file, suggesting limited raw data scope; the primary content is likely the analysis document.
• Column-level documentation is absent; field semantics must be inferred after download.
• Findings for SGLT2 inhibitors are noted as preliminary, based on limited histological data from a single pivotal trial.

Provenance

Source

figshare

Collection Method

Systematic literature review and frequentist network meta-analysis of published Phase II/III RCTs.

Freshness

Last updated 2026-06-04 04:30:35.